Nassim Usman
Directeur Général chez Totus Medicines, Inc.
Fortune : 27 153 $ au 30/06/2024
Profil
Nassim Usman is currently the President & Chief Executive Officer at Totus Medicines, Inc. He is also an Independent Director at LifeSci Acquisition III Corp.
Previously, he held positions such as Chief Executive Officer & Director at Catalyst Bioscience, Inc. from 2011 to 2015, and President, Chief Executive Officer & Director at Catalyst Biosciences, Inc. from 2015 to 2023.
He has also served as a Director at Archemix Corp., Principia Biopharma, Inc., Mosaic Biosciences, Inc., NOXXON Pharma AG, Atugen AG, and Osprey Pharmaceuticals Ltd.
Additionally, he was an Independent Director at Gyre Therapeutics, Inc. from 2023 to 2024.
Earlier in his career, he was the Chief Operating Officer & Senior Vice President at Sirna Therapeutics, Inc. from 2004 to 2005.
He has also worked as a Principal at Phio Pharmaceuticals Corp.
and as a Venture Partner at LSV Capital Management LLC.
Dr. Usman obtained his undergraduate and doctorate degrees from McGill University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,00% | 28/06/2024 | 2 276 ( 0,00% ) | 27 153 $ | 30/06/2024 |
Postes actifs de Nassim Usman
| Sociétés | Poste | Début |
|---|---|---|
LifeSci Acquisition III Corp.
 LifeSci Acquisition III Corp. Financial ConglomeratesFinance LifeSci Acquisition III Corp. operates as a blank check company with the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on December 18, 2019 and is headquartered in new York, NY. | Directeur/Membre du Conseil | - |
Totus Medicines, Inc.
 Totus Medicines, Inc. Pharmaceuticals: MajorHealth Technology Totus Medicines, Inc. manufactures drug products. The company is based in Cambridge, MA. The company was founded by Neil Dhawan, Jason Pontin. Neil Dhawan has been the CEO since incorporation. | Directeur Général | 15/12/2023 |
Anciens postes connus de Nassim Usman
| Sociétés | Poste | Fin |
|---|---|---|
Catalyst Bioscience, Inc. /Old/
 Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | Directeur Général | 01/08/2015 |
Osprey Pharmaceuticals Ltd.
 Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | Directeur/Membre du Conseil | 29/06/2012 |
Sirna Therapeutics, Inc.
 Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Directeur des opérations | 01/01/2005 |
| CATALYST BIOSCIENCES | Directeur Général | 30/10/2023 |
Formation de Nassim Usman
| McGill University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PHIO PHARMACEUTICALS CORP. | Health Technology |
| Entreprise privées | 12 |
|---|---|
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Commercial Services |
Archemix Corp.
 Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | Commercial Services |
Catalyst Bioscience, Inc. /Old/
Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
Mosaic Biosciences, Inc.
 Mosaic Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Mosaic Biosciences, Inc. provides commercial research and development services. It conducts research on synthetic materials that support native tissue regeneration. The firm's solutions are designed for application in wound healing, bone regeneration, cartilage repair, stem cell therapy, and dermal fillers. The company was founded by Martin Stanton, Chris Bowman, Kristi S. Anseth and Peter Mariner in 2009 and is headquartered in Boulder, CO. | Commercial Services |
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Health Technology |
Atugen AG
 Atugen AG Pharmaceuticals: MajorHealth Technology Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany | Health Technology |
Osprey Pharmaceuticals Ltd.
Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | Health Technology |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
Totus Medicines, Inc.
Totus Medicines, Inc. Pharmaceuticals: MajorHealth Technology Totus Medicines, Inc. manufactures drug products. The company is based in Cambridge, MA. The company was founded by Neil Dhawan, Jason Pontin. Neil Dhawan has been the CEO since incorporation. | Health Technology |
LifeSci Acquisition III Corp.
LifeSci Acquisition III Corp. Financial ConglomeratesFinance LifeSci Acquisition III Corp. operates as a blank check company with the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on December 18, 2019 and is headquartered in new York, NY. | Finance |
LSV CAPITAL MANAGEMENT LLC
 LSV CAPITAL MANAGEMENT LLC Investment ManagersFinance LSV Capital Management LLC (Lightstone Ventures) is a venture capital firm founded in 2012. The firm is headquartered in Menlo Park, California. | Finance |
